NeurAxon Pharma Inc

H.I.G. Capital, a global private equity firm with more than $8.5 billion under management, has closed its second life sciences-focused venture fund - H.I.G. BioVentures II – at $268 million, exceeding

After numerous spectacular failures, investors and Big Pharma are pulling back from novel pain drug development, but they risk losing out on improving R&D in the field. By Marc Wortman Pain has been a

Cambridge-based biotech Bicycle Therapeutics has appointed Andy Sandham as non-executive chairman. Mr Sandham held previous roles at Cantab Pharmaceuticals, Hexagen, Signature BioScience and Ionix Pha

In Vitro Diagnostics Boston Heart Lab Corp. Boston Heart Lab brings in $10mm through its Series C round Sep. — Boston Heart Lab Corp. (heart disease diagnostics) has raised $10mm through the closi